Skip to main content
Top
Published in: Supportive Care in Cancer 1/2006

01-01-2006 | Original Article

No pain relief from morphine?

Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients

Authors: Julia Riley, Joy R. Ross, Dag Rutter, Athol U. Wells, Katherine Goller, Ron du Bois, Ken Welsh

Published in: Supportive Care in Cancer | Issue 1/2006

Login to get access

Abstract

Goals of work

The aims of this study were (1) to prospectively evaluate the clinical benefits of switching from morphine to an alternative opioid, using oxycodone as first-line alternative opioid, in patients with cancer, (2) to evaluate the consistency of the clinical decision for the need to switch by comparing two hospital sites, and (3) to evaluate whether there were objective predictors that would help identify morphine non-responders who require switching to an alternative opioid and from this to construct a clinical model to predict the need to switch.

Patients and methods

One hundred eighty-six palliative care patients were prospectively recruited from two hospital sites. Responders were patients treated with morphine for more than 4 weeks with good analgesia and minimal side effects. Non-responders (switchers) were patients who had either uncontrolled pain or unacceptable side effects on morphine and therefore required an alternative opioid. The differentiation between responders and switchers was made clinically and later confirmed by objective parameters.

Results

In this prospective study 74% (138/186) had a good response to morphine (responders). One patient was lost to follow up. Twenty-five percent (47/186) did not respond to morphine. These non-responders were switched to alternative opioids (switchers). Furthermore, of 186 patients, 37 achieved a successful outcome when switched to oxycodone and an additional 4 were well controlled when switched to more than one alternative opioid. Overall successful pain control with minimal side effects was achieved in 96% (179/186) of patients. There were no significant differences in the need to switch between the two hospital sites.

Conclusions

This study has shown that proactive clinical identification and management of patients that require opioid switching is reproducible in different clinical settings and significantly improves pain control. Further studies are required to develop and test the predictive model.
Literature
1.
go back to reference World Health Organisation (1996) Cancer pain relief, 2nd edn. World Health Organisation, Geneva World Health Organisation (1996) Cancer pain relief, 2nd edn. World Health Organisation, Geneva
2.
go back to reference Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P et al (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19(11):2898–2904PubMed Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P et al (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19(11):2898–2904PubMed
3.
go back to reference de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10(5):378–384CrossRefPubMed de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10(5):378–384CrossRefPubMed
4.
go back to reference Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8(2):63–67CrossRefPubMed Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8(2):63–67CrossRefPubMed
5.
go back to reference Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73(2):151–157CrossRefPubMed Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73(2):151–157CrossRefPubMed
6.
go back to reference Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T (1990) Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 67(4):322–328 Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T (1990) Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 67(4):322–328
7.
go back to reference Saarialho-Kere U, Mattila MJ, Seppala T (1989) Psychomotor, respiratory and neuroendocrinological effects of a mu-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 65(4):252–257PubMed Saarialho-Kere U, Mattila MJ, Seppala T (1989) Psychomotor, respiratory and neuroendocrinological effects of a mu-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 65(4):252–257PubMed
8.
go back to reference Gagnon B, Bielech M, Watanabe S, Walker P, Hanson J, Bruera E (1999) The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer 7:265–270 Gagnon B, Bielech M, Watanabe S, Walker P, Hanson J, Bruera E (1999) The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer 7:265–270
9.
go back to reference Kalso E, Vainio A (1990) Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47:639–646 Kalso E, Vainio A (1990) Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47:639–646
10.
go back to reference Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T (1991) Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 35:642–646PubMed Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T (1991) Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 35:642–646PubMed
11.
go back to reference Mercadante S (1999) Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86(9):1856–1866CrossRefPubMed Mercadante S (1999) Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86(9):1856–1866CrossRefPubMed
12.
go back to reference Riley J, Ross JR, Rutter D, Shah S, Gwilliam B, Wells AU et al (2004) A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain. Palliat Med 18(1):19–24CrossRefPubMed Riley J, Ross JR, Rutter D, Shah S, Gwilliam B, Wells AU et al (2004) A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain. Palliat Med 18(1):19–24CrossRefPubMed
13.
go back to reference D’Honneur G, Gilton A, Sandouk P, Scherrmann M, Duvaldestin P (1994) Plasma and cerebrospinal fluid concentrations of morphine and morphine gluronides after oral morphine. The influence of renal failure. Anesthesiology 81:87–93PubMed D’Honneur G, Gilton A, Sandouk P, Scherrmann M, Duvaldestin P (1994) Plasma and cerebrospinal fluid concentrations of morphine and morphine gluronides after oral morphine. The influence of renal failure. Anesthesiology 81:87–93PubMed
14.
go back to reference Farrell A, Rich A (2000) Analgesic use in patients with renal failure. Eur J Palliat Care 7(6):201–205 Farrell A, Rich A (2000) Analgesic use in patients with renal failure. Eur J Palliat Care 7(6):201–205
15.
go back to reference Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J (1990) The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 29(3):289–297PubMed Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J (1990) The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 29(3):289–297PubMed
16.
go back to reference Lesage P, Portenoy RK (1999) Trends in cancer pain management. Cancer Control 6(2):136–145PubMed Lesage P, Portenoy RK (1999) Trends in cancer pain management. Cancer Control 6(2):136–145PubMed
17.
go back to reference Regan J, Yarnold J, Jones PW, Cooke NT (1991) Palliation and life quality in lung cancer; how good are clinicians at judging treatment outcome? Br J Cancer 64(2):396–400 Regan J, Yarnold J, Jones PW, Cooke NT (1991) Palliation and life quality in lung cancer; how good are clinicians at judging treatment outcome? Br J Cancer 64(2):396–400
18.
go back to reference Quigley C (2004) Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 3:CD004847 Quigley C (2004) Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 3:CD004847
19.
go back to reference Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M (1995) Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10(4):287–291CrossRefPubMed Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M (1995) Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10(4):287–291CrossRefPubMed
20.
go back to reference Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B et al (1995) Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76(7):1283–1293PubMed Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B et al (1995) Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76(7):1283–1293PubMed
21.
go back to reference Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64(6):603–611 Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64(6):603–611
Metadata
Title
No pain relief from morphine?
Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients
Authors
Julia Riley
Joy R. Ross
Dag Rutter
Athol U. Wells
Katherine Goller
Ron du Bois
Ken Welsh
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0843-2

Other articles of this Issue 1/2006

Supportive Care in Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine